VVOS's Business Model
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
| Sector & Industry | Healthcare / Medical - Devices |
| Website | https://vivos.com |
| CEO (Chief Executive Officer) | R. Kirk Huntsman |
| Number of Employees | |
| IPO date | December 11, 2020 |
VVOS Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 9137 Ridgeline Boulevard |
| City | Highlands Ranch |
| State | CO |
| Phone | 866 908 4867 |
| Zip Code | 80129 |
| Other Identifiers | |
| CIK | 0001716166 |
| ISIN | US92859E2072 |
| CUSIP | 92859E108 |
| Open | 3.89 |
| Previous Close | 3.83 |
| Volume | 994.5 Thou. |
| Average Volume | 625.7 Thou. |
| Day’s Range | 3.875 – 4.5 |
| 52 Week Range | 1.97-6.28 |
| MA (50) | 2.6249 |
| MA (200) | 3.24992 |
| Market Cap | 26.09 Mil. |
| Shares Out. | 5.89 Mil. |
| Earnings Date | Aug 12, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
Industry Competitors for VVOS
|
Company
|
PE Ratio | Market Cap |
|---|---|---|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
